Meta-analysis of randomized trials on first line and adjunctive levetiracetam

Canadian Journal of Neurological Sciences

Volumn 38, Issue 3, 2011, Pages 475-486

  Lo, Benjamin ^a,b   Kyu, Hmwe ^a   Jichici, Draga ^a   Upton, Adrian ^a   Akl, Elie ^a,c   Meade, Maureen ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; PHENYTOIN; PLACEBO; VALPROIC ACID;

ADD ON THERAPY; ADJUVANT THERAPY; ARTICLE; BLOOD DISEASE; BLOOD DYSCRASIAS; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FOCAL EPILEPSY; FOLLOW UP; GENERALIZED EPILEPSY; HUMAN; IRRITABILITY; MEDICAL LITERATURE; META ANALYSIS; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; SEIZURE; SENSITIVITY ANALYSIS; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TONIC CLONIC SEIZURE; UNSPECIFIED SIDE EFFECT;

EID: 79955495022     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100011902     Document Type: Article

References (24)

1. Cereghino J, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures -results of a double-blind, randomized clinical trial. Neurology. 2000;55:236-42. (Pubitemid 30604624)
2. French J, Edrich P, Cramer J. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 2001;47:77-90. (Pubitemid 32973650)
3. Leppik I, Morrell M, Godfroid P, et al. Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy. Epilepsia. 2003;44(10):1350-2. (Pubitemid 37280380)
4. Otoul C, Arrigo C, van Rijckevorsel, et al. Meta-analysis and indirect comparisons of levetiracetam with other secondgeneration antiepileptic drugs in partial epilepsy. Clin Neuropharmacol. 2005;28(2):72-8. (Pubitemid 40471880)
5. Cramer J, De Rue K, Devinsky O, et al. A systematic review of the behavioural effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav. 2003;4:124-32. (Pubitemid 37184583)
6. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. The Cochrane Collaboration [cited 2009 Sep 29]. Available from www.cochrane-handbook.org.
7. Guyatt G, Oxman A, Vist G, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-7.
8. Schunemann H, Jaeschke R, Cook D, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med. 2006;174(5):605-14. (Pubitemid 44330555)
9. Daya S. Funnel plots and publication bias -work in progress? Evidence-based Obstet and Gynecol. 2006;8:71-2. (Pubitemid 44734492)
10. Berkovic S, Knowlton R, Leroy R, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology. 2007;69:1751-60. (Pubitemid 350059304)
11. Jones K, Puccio A, Harshman K, et al. Levetiraectam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurg Focus. 2008;25(4):e1-5.
12. Lim D, Tarapore P, Chan E, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J. Neurooncol. 2009;93(3):349-54.
13. Milligan T, Hurwitz S, Bromfield E, et al. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology. 2008;71:665-9.
14. Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology. 2008;70:607-16. (Pubitemid 351294638)
15. Steinhoff B, Somerville E, van Paesschen W, et al. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Epilepsy Res. 2007;76(1):6-14. (Pubitemid 47243697)
16. Szaflarski J, Sangha K, Lindsell C, et al. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010; 12(2):165-72.
17. Brodie M, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402-8. (Pubitemid 46208740)
18. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia. 2000;41(10):1276-83.
19. Shorvon S, Löwenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia. 2000;41(9):1179-86.
20. Peltola J, Coetzee C, Jimenez F, et al. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebocontrolled trial. Epilepsia. 2009;50(3):406-14.
21. Xiao Z, Li J-M, Wang X-F, et al. Efficacy and safety of levetiracetam (3000 mg/day) as an adjunctive therapy in Chinese patients with refractory partial seizures. Eur Neurol. 2009;61: 233-9.
22. Wu X-Y, Hong Z, Wu X, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Epilepsia. 2009;50(3):398-405.
23. Tsai J-J, Yen D-J, Hsih M-S, et al. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, doubleblind, placebo-controlled study. Epilepsia. 2006;47(1):72-81.
24. Betts T, Waegemans T, Crawford P. A multicenter, double-blind, randomized, parallel group study to evaluate to the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000;9:80-7. (Pubitemid 30209795)